Researchers explored whether clinical frailty assessment impacts outcomes of CAR-T therapy and whether changes in frailty before and after therapy affect outcomes.

Researchers sought to determine the effects of second-line to third-line therapy sequence for relapsed/refractory T and NK-cell neoplasms on OS and real world PFS.

Researchers report on the rates of CRS and ICANS in patients with relapsed/refractory B-ALL who are treated with brexucabtagene autoleucel.

Tacrolimus/methotrexate (Tac/MTX) is standard prophylaxis against GVHD in patients undergoing HSCT.

Researchers used multiplexed IHC to identify steroid-sensitive GI aGVHD vs steroid-refractory GI aGVHD, a life-threatening late effect of HCT.

Researchers explored the pathogenesis of bronchiolitis obliterans syndrome as a late-effect of cGVHD in patients undergoing allo-HSCT.

This study sought to determine if RIC conditioning regimen would lead to better outcomes for patients with MDS undergoing allo-HCT.

A research team investigated whether use of posttransplant cyclophosphamide would mitigate outcomes disparity in racial and ethnic minority patients.

A pilot project developed a 30-day program for remote patient monitoring after CAR-T therapy to determine whether this therapy could be safely administered in the outpatient setting.

Research results demonstrate that substance use and psychiatric disorders have a negative effect on mortality among veterans with AML receiving venetoclax.